Ada Health Secures £63m Investment to Enhance Assessment Tech
Ada Health has secured $90m (£63m) in funding to enhance its health assessment technology.
The investment will enable Ada to work towards becoming the world’s leading personalised operating system for health, according to a statement from the digital health company.
It will also be used to expand its offering in the United States.
The Berlin-based digital health company received Series B investment from Leaps by Bayer, the investment arm of Bayer, as well as six other investors including Samsung.
Ada Health provides an AI-based health assessment and care navigation platform to help patients better understand their symptoms and navigate the right care pathways at the right time.
The app has completed more than 23 million assessments since its launch in 2016.
Dr. Jürgen Eckhardt, head of Leaps by Bayer, said: “Investing in breakthrough technologies that drive digital change in healthcare is one of the strategic imperatives for Leaps by Bayer and for the entire field of healthcare.
“Ada’s truly transformative technology, combining powerful artificial intelligence with an emphasis on medical rigor and high levels of clinical accuracy will lead the way in helping more patients and consumers in achieving better health outcomes sooner by intervening earlier in their healthcare journey.”
Daniel Nathrath, chief executive and co-founder of Ada Health added: “Today’s investment will help bring us closer to our goal of improving healthcare outcomes for more than one billion people around the world.
“We’re proud to have investors on board who truly believe in Ada’s technology and vision of transforming the way people access healthcare. We are thrilled to have Leaps by Bayer as the lead investor particularly as our values are very much aligned with putting science and technology as well as a commitment to medical quality and user-centricity at the heart of everything we do.”
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more